SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Podcast
Novo Grilled by Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval
New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated approval for schizophrenia.
September 25, 2024
 · 
1 min read
 · 
Heather McKenzie
Novo Nordisk's logo on the facade of its building in Germany
Policy
Novo’s Ozempic Seen as Shoo-In for Next Round of Medicare Price Negotiations
Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices will be negotiated in 2025 and go into effect in 2027, according to analysts and academics.
September 25, 2024
 · 
3 min read
 · 
Greg Slabodkin
Deals
Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s
Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in licensing and M&A deals.
September 25, 2024
 · 
10 min read
 · 
Annalee Armstrong
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
Bluebird Bio to Lay Off 25% of Workforce
About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it will lay off about 25% of its employees, over half of whom work in R&D.
September 24, 2024
 · 
1 min read
 · 
Angela Gabriel
Mechanical weight scale, body mass control concept : Bathroom scale on pale blue wood background. Analog scale operated with spring that pressure is calibrated to translate tension into a mass readout.
Weight Loss
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss, Few Side Effects
Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal side effects.
September 24, 2024
 · 
2 min read
 · 
Annalee Armstrong
Robot hand with gear wheels. 3d illustration.
Deals
Flagship’s AI Company Generate Inks Deal Worth up to $1B With Novartis
Flagship Pioneering–backed Generate:Biomedicines has signed its second major Big Pharma partnership, bringing in $65 million upfront to use its AI platform to discover novel protein drug candidates.
September 24, 2024
 · 
2 min read
 · 
Annalee Armstrong
Rusty lung. Cancer and health concept. This is a 3d render illustration.
Drug development
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
September 24, 2024
 · 
4 min read
 · 
Heather McKenzie
External view of the U.S. Capitol building at sunset
Drug pricing
Amgen, Lilly Are Part of Ongoing Senate Probe Into Pharma’s Restrictions on 340B Program
A senior senator has asked the CEOs of both companies to provide information about the limits they are putting on 340B drug pricing for hospitals.
September 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boy in a wheelchair looking out the window
Neurodegenerative disease
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia
The FDA previously refused to review Biohaven’s candidate in the indication due to a failed late-stage trial. However, the company is now planning to file an NDA in the fourth quarter of 2024.
September 24, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS